Preclinical Oncology

In 2019 Covance welcomed the preclinical pharmacology oncology provider, MI Bioresearch, to the Covance family. Now, you have access to hundreds of oncology and immuno-oncology tumor models as well as cell-line assays

Tumor Model Spotlights

E0771: Syngeneic Breast Cancer Model

Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer lacking estrogen receptor, progesterone receptor, and HER2 amplifications; making it difficult to target therapeutically. Consequently, there’s a constant demand for better treatment options for TNBC. . . 

LL/2: Immunosuppressive Murine Model

Lung cancer is the second most common cancer diagnosed in both men and women in the United States and is, by far, the most common cause of cancer-related deaths in men and women. In 2019, the American Cancer Society estimates that 228,150 new cases of lung cancer . . . 

EMT-6: Syngeneic Breast Tumor Model

Breast cancer is the most common cancer among women in the United States and is the fourth leading cause of cancer death. In 2017, an estimated 252,710 new cases were diagnosed (15% of all new cancers) and 40,610 patient deaths occurred. Early detection initiatives together with improved treatment . . . 

B16-F10: A Murine Melanoma Model

Skin cancers include carcinomas of all layers of the skin with the most common being basal cell (BCC) and squamous cell carcinomas (SCC). Melanoma and non-melanoma skin cancers (Merkel cell carcinoma, Kaposi sarcoma, cutaneous lymphoma and other sarcomas) are much less common. . . .